E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
Hagop M. Kantarjian,Mikkael A. Sekeres,Vincent Ribrag,Philippe Rousselot,Guillermo Garcia-Manero,Elias Jabbour,Kate Owen,Paul K. Stockman,Stuart Oliver +8 more
TL;DR: The MTD of 1000 mg barasertib in combination with LDAC in older patients with AML was associated with acceptable tolerability and preliminary anti-AML activity.
Journal ArticleDOI
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome–negative acute lymphoblastic leukemia in the era of minimal residual disease
Ghayas C. Issa,Hagop M. Kantarjian,C. Cameron Yin,Wei Qiao,Farhad Ravandi,Deborah A. Thomas,Nicholas J. Short,Koji Sasaki,Guillermo Garcia-Manero,Tapan M. Kadia,Jorge E. Cortes,Naval Daver,Gautam Borthakur,Nitin Jain,Marina Konopleva,Issa F. Khouri,Partow Kebriaei,Richard E. Champlin,Sherry Pierce,Susan O'Brien,Elias Jabbour +20 more
TL;DR: The introduction of novel prognostic factors such as minimal residual disease (MRD) and genomic profiling has led to the reevaluation of the role of cytogenetics and other conventional factors in risk stratification for acute lymphoblastic leukemia.
Journal ArticleDOI
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia
Yoshihiro Gocho,Jingjing Liu,Jianzhong Hu,Wentao Yang,Neekesh V. Dharia,Neekesh V. Dharia,Jingliao Zhang,Hao Shi,Guoqing Du,August John,Ting Nien Lin,Jeremy Hunt,Xin Huang,Bensheng Ju,Lauren Rowland,Lei Shi,Dylan Maxwell,Brandon Smart,Kristine R. Crews,Wenjian Yang,Kohei Hagiwara,Yingchi Zhang,Kathryn G. Roberts,Hong Wang,Elias Jabbour,Wendy Stock,Bartholomew J. Eisfelder,Elisabeth Paietta,Scott Newman,Giovanni Roti,Giovanni Roti,Mark R. Litzow,John Easton,Jinghui Zhang,Junmin Peng,Hongbo Chi,Stanley Pounds,Mary V. Relling,Hiroto Inaba,Xiaofan Zhu,Steven M. Kornblau,Ching-Hon Pui,Marina Konopleva,David T. Teachey,Charles G. Mullighan,Kimberly Stegmaier,Kimberly Stegmaier,William E. Evans,Jiyang Yu,Jun J. Yang +49 more
TL;DR: The results indicate that developmental arrest in T-ALL drives differential activation of preTCR-LCK and BCL2 signaling in this leukemia, providing unique opportunities for targeted therapy.
Journal ArticleDOI
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome
M. de Lima,Richard E. Champlin,Peter F. Thall,X. Wang,Thomas G. Martin,J D Cook,Gloria McCormick,M.H. Qazilbash,Partow Kebriaei,Daniel R. Couriel,Elizabeth J. Shpall,Issa F. Khouri,P. Anderlini,Chitra Hosing,Kawah Chan,Borje S. Andersson,Poliana A. Patah,Z. Caldera,Elias Jabbour,Sergio Giralt +19 more
TL;DR: GO 2 mg m−2 can be safely added to fludarabine/melphalan, and this regimen merits further evaluation.
Journal ArticleDOI
More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia
Guillermo Montalban-Bravo,Christopher B. Benton,Sa A. Wang,Farhad Ravandi,Tapan M. Kadia,Jorge E. Cortes,Naval Daver,Koichi Takahashi,Courtney D. DiNardo,Elias Jabbour,Gautam Borthakur,Marina Konopleva,Sherry Pierce,Carlos E. Bueso-Ramos,Keyur P. Patel,Steven M. Kornblau,Hagop M. Kantarjian,Ken H. Young,Guillermo Garcia-Manero,Michael Andreeff +19 more
TL;DR: PEL, or AML-M6b, is a rare form of leukemia characterized by proliferation of >80% undifferentiated or pronormoblastic immature cells committed exclusively to the erythroid lineage.